Related references
Note: Only part of the references are listed.Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study
Delphine Rea et al.
BLOOD (2017)
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia
Gabriele Gugliotta et al.
HAEMATOLOGICA (2017)
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia
Gabriel Etienne et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study
A. Hochhaus et al.
LEUKEMIA (2017)
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia
Gabriele Gugliotta et al.
HAEMATOLOGICA (2017)
Bosutinib (BOS) versus imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE trial.
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study
A. Hochhaus et al.
LEUKEMIA (2016)
Moving treatment-free remission into mainstream clinical practice in CML
Timothy P. Hughes et al.
BLOOD (2016)
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival A Systematic Review and Meta-analysis
Jonathan Douxfils et al.
JAMA ONCOLOGY (2016)
The impact of dasatinib on pregnancy outcomes
Jorge E. Cortes et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
A review of the European LeukemiaNet recommendations for the management of CML
Michele Baccarani et al.
ANNALS OF HEMATOLOGY (2015)
Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era
Niklas Gunnarsson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial
Jun Imagawa et al.
LANCET HAEMATOLOGY (2015)
Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease
Philippe Rousselot et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
Stacie B. Dusetzina et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience
Ohad Benjamini et al.
LEUKEMIA & LYMPHOMA (2014)
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors
Lorenzo Falchi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
David M. Ross et al.
BLOOD (2013)
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience
Hagop Kantarjian et al.
BLOOD (2012)
Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies
Dushyant Verma et al.
BLOOD (2011)
Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib?
Sheila A. Doggrell et al.
EXPERT OPINION ON PHARMACOTHERAPY (2011)
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
Timothy P. Hughes et al.
BLOOD (2010)
Heart failure with preserved versus reduced left ventricular systolic function: A prospective cohort of Shinken Database 2004-2005
Ayumi Goda et al.
JOURNAL OF CARDIOLOGY (2010)
Relapse and Late Mortality in 5-Year Survivors of Myeloablative Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia in First Chronic Phase
John M. Goldman et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
GADD34 suppresses wound healing by upregulating expression of myosin IIA
Chie Tanaka et al.
TRANSGENIC RESEARCH (2010)
Immunolocalization of lingual antimicrobial peptide (LAP) in the bovine mammary gland
Naoki Isobe et al.
ANIMAL SCIENCE JOURNAL (2009)
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pregnancy among patients with chronic myeloid leukemia treated with imatinib
P Ault et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
